Increased PAI activity and PAI-1 antigen occurring with an oral fat load: Associations with PAI-1 genotype and plasma active TGF-β levels

Atherosclerosis

Volumn 140, Issue 1, 1998, Pages 45-53

  Byrne, C D ^a   Wareham, N J ^b   Martensz, N D ^a   Humphries, S E ^c   Metcalfe, J C ^d   Grainger, D J ^a,d  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Fat tolerance test; Genotype; Plasminogen activator inhibitor (PAI); Transforming growth factor (TGF )

Indexed keywords

LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ALLELE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; DIET; FAT INTAKE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PLASMINOGEN ACTIVATION; POSTPRANDIAL STATE; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS; WEIGHT REDUCTION;

EID: 0032171433     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00108-7     Document Type: Article

References (46)

1. Zilversmit D.B. Atherogenesis: a post prandial phenomenon. Circulation. 60:1979;473-485.
2. Stender S., Zilversmit D.B. Comparison of cholesteryl ester transfer from chylomicrons and other plasma lipoproteins to aorta intima-media of cholesterol-fed rabbits. Arteriosclerosis. 2:1982;493-499.
3. Simons L.A., Dwyer T., Simons J., Bernstein P., Mock P., Poonia N.S., Balasubramanian S., Baron D., Branson J., Morgan J., Roy P. Chylomicrons and chylomicron remnants in coronary artery disease: a case control study. Atherosclerosis. 65:1987;181-189.
4. Simpson H.S., Williamson C.M., Olivecrona T., Pringle S., Maclean J., Lorimer A.R., Bonnefous F., Bogaievsky Y., Packard C.J., Shepherd J. Post prandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis. 85:1990;193-202.
5. Groot P.H.E., van Stiphout W.A., Krauss X.H., Jansen H., van Tol A., van Ramshorst E., Chin-On S., Hofman A., Cresswell S.R., Havekes L. Post prandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb. 11:1991;653-662.
6. Patsch J.R., Miesenbock G., Hopferwieser T., Muhlberger V., Knapp E., Dunn J.K., Gotto A.M. Jr., Patsch W. Relation of triglyceride metabolism and coronary artery disease: studies in the post prandial state. Arterioscler Thromb. 12:1992;1336-1345.
7. Karpe F., Bard J.M., Steiner G., Carlson L.A., Fruchart J.C., Hamstem A. HDLs and alimentary lipemia. Studies in men with previous myocardial infarction at a young age. Arterioscler Thromb. 13:1993;11-22.
8. JuhanVague I., Thompson S.G., Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. Arterioscler Thromb. 13:1993;1865-1873.
9. Asplund-Carlson A., Hamsten A., Wiman B., Carlson L.A. Relationship between plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo-and hypertriglyceridaemic men. Diabetologia. 36:1993;817-825.
10. Mussoni L., Mannucci L., Sirtori M., Camera M., Maderna P., Sironi L., Tremoli E. Hypertriglyceridaemia and regulation of fibrinolytic activity. Arterioscler Thromb. 12:1992;19-27.
11. Kozima Y., Urano T., Serizawa K., Takada Y., Takada A. Impaired fibrinolytic activity induced by ingestion of butter: effect of increased plasma lipids on the fibrinolytic activity. Thromb Res. 70:1993;191-202.
12. Grainger D.J., Kirschenlohr H.L., Metcalfe J.C., Weissberg P.L., Wade D.P., Lawn R.M. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 260:1993;1655-1658.
13. Sato Y., Tsuboi R., Lyons R., Moses H., Rifkin D.B. Characterization of the activation of latent TGF-β by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system. J Cell Biol. 111:1990;757-763.
14. Grainger D.J., Witchell C.M., Metcalfe J.C. Tamoxifen elevates transforming growth factor beta and suppresses diet-induced formation of lipid lesions in mouse aorta. Nat Med. 1:1995;1067-1073.
15. Gamble J.R., Khew-Goodall Y., Vadas M.A. Transforming growth factor-beta inhibits E-selectin expression on human endothelial cells. J Immunol. 150:1993;4494-4503.
16. Shull M.M., Ormsby I., Kier A.B., Pawlowski S., Diebold R.J., Yin M., Allen R., Sidman C., Proetzel G., Calvin D., Annunziata N., Doetschman T. Targeted disruption of the mouse transforming growth factor beta-1 gene results in multifocal inflammatory disease. Nature. 359:1992;693-699.
17. Kulkarni A.B., Ward J.M., Yaswen L., Mackall C.L., Bauer S.R., Huh C.G., Gress R.E., Karlsson S. Transforming growth factor beta-1 null mice. An animal model for inflammatory disorders. Am J Pathol. 146:1995;264-275.
18. Grainger D.J., Metcalfe J.C. A pivotal role for TGF-beta in atherogenesis? Biol Rev Cambridge Philosophical Soc. 70:1995;571-596.
19. Grainger D.J., Metcalfe J.C. Tamoxifen - teaching an old drug new tricks? Nat Med. 2:1996;381-385.
20. Geppert A., Beckmann R., Graf S., Hornykewycz S., Lang I., Schuster E., Binder B.R., Huber K. Tissue-type plasminogen activator and type-1 plasminogen activator inhibitor in patients with coronary artery disease - relations to clinical variables and cardiovascular risk factors. Fibrinolysis. 9:1995;109-113.
21. DeBono D. Significance of raised plasma concentrations of tissue-plasminogen activator and plasminogen activator inhibitor in patients at risk from ischemic heart disease. Br Heart J. 71:1994;504-507.
22. Grainger D.J., Kemp P.R., Metcalf J.C., Liu A.C., Lawn R.M., Williams N.R., Grace A.A., Schofield P.M., Chauhan A. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nat Med. 1:1995;74-79.
23. Dawson S.J., Hamsten A., Wiman B., Henney A., Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma PAI-1 activity. Arterioscler Thromb. 11:1991;183-190.
24. Dawson S.J., Wiman B., Hamsten A., Green F., Humphries S., Henney A.M. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 268:1993;10739-10745.
25. Eriksson P., Kallin B., van-'t-Hooft F.M., Bavenholm P., Hamsten A. Allele-specific increase in basal transcription of the plasminogen activator inhibitor-1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA. 92:1995;1851-1855.
26. Ridker P.M., Hennekens C.H., Lindpaintner K., Stampfer M.J., Miletich J.P. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator gene in a large cohort of US men. Circulation. 95:1997;59-62.
27. Panahloo A., Mohamed-Ali V., Lane A., Green F., Humphries S.E., Yudkin J.S. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes. 44:1995;37-42.
28. Mansfield M.W., Strickland M.H., Grant P.J. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor 1 in Caucasian patients with non-insulin dependent diabetes mellitus. Thromb Haemost. 74:1995;842-847.
29. Barker D.J.P., Hales C.N., Fall C.H.D., Osmond C., Phipps K., Clark P.M.S. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia. 36:1993;62-67.
30. Patsch J.R., Karlin J.B., Scott L.W., Smith L.C., Gotto A.M. Jr. Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of post prandial lipemia. Proc Natl Acad Sci USA. 80:1983;1449-1453.
31. Grainger D.J., Wakefield L., Bethell H.W., Farndale R.W., Metcalfe J.C. Release and activation of platelet latent TGFβ in blood clots during dissolution with plasmin. Nat Med. 1:1995;932-937.
32. Berruyer M., Ville D., Ffrench P., Trzeciak M.C., Dechavanne M. Dosage immunoenzymologique de la β-thromboglobuline et du facteur plaquettaire 4: corrélation avec un dosage radioimmunologique. Int Sci Biol. 13:1987;187-194.
33. Havel R.J., Eder H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 34:1955;1345-1353.
34. Kunst A, Draeger B, Ziegenhorn J. UV-methods with hexokinase and glucose-6-phosphate dehydrogenase. In: Bergmeyer HU, editor. Methods of Enzymatic Analysis, vol VI. Deerfield: Weinheim Verlag Chemie, 1983:163-172.
35. Sobey W.J., Beer S.F., Carrington C.A., Clark P.M.S., Frank B.H., Gray I.P., Luzio S.D., Owens D.R., Schneider A.K., Siddle K., Hales C.N. Sensitive and specific two site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins. Biochem J. 260:1989;535-541.
36. Alpha B., Cox L., Crowther N., Clark P.M.S., Hales C.N. Sensitive amplified immunoenzymometric assays (IEMA) for human insulin and intact proinsulin. Eur J Clin Chem Clin Biochem. 30:1992;27-32.
37. Grainger D.J., Mosedale D.E., Metcalfe J.C., Weissberg P.L., Kemp P.R. Active and acid-activatable TGF-beta in human sera, platelets and plasma. Clin Chim Acta. 235:1995;11-31.
38. Grainger D.J., Byrne C.D., Witchell C.M., Metcalfe J.C. Transforming growth factor-β is sequestered into an inactive pool by lipoprotein particles. J Lipid Res. 38:1997;2344-2352.
39. Kojima S., Harpel P.C., Rifkin D.B. Lipoprotein(a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol. 113:1991;1439-1445.
40. Grainger D.J., Kemp P.R., Liu A.C., Lawn R.M., Metcalfe J.C. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature. 370:1994;460-462.
41. Brown S.A., Morrisett J., Patsch J.R., Reeves R., Gotto A.M. Jr., Patsch W. Influence of short term dietary cholesterol and fat on human plasma Lp(a) and LDL levels. J Lipid Res. 32:1991;1281-1289.
42. Wiman B., Hamsten A. The fibrinolytic enzyme system and its role in the aetiology of thromboembolic disease. Semin Thromb Haemost. 16:1990;207-216.
43. Nordt T.K., Sawa H., Fujii S., Sobel B.E. Induction of plasminogen-activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation. 91:1995;764-770.
44. McCaffrey T.A., Falcone D.J., Brayton C.F., Agawal L.A., Welt F.G., Weksler B.B. Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha-2-macroglobulin inactive complex. J Cell Biol. 109:1989;441-448.
45. Grainger D.J., Witchell C.M., Watson J.V., Metcalfe J.C., Weissberg P.L. Heparin decreases the rate of proliferation of rat vascular smooth muscle cells by releasing transforming growth factor beta-like activity from serum. Cardiovasc Res. 27:1993;2238-2247.
46. Karpe F., Olivecrona T., Walldius G., Hamsten A. Lipoprotein lipase in plasma after an oral fat load: relation to free fatty acids. J Lipid Res. 33:1992;975-984.